REGENXBIO Inc. (RGNX) stock
RGNXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$7.24−0.08 (-1.09%)
Close on Nov 17, 2026Market cap $477.94MP/E –Yield –
Regenxbio profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Regenxbio's profit margin for the twelve months ending Jun 30, 2026 was -112.6%. For fiscal 2025 it was -113.8%, against -272.5% the year before. The highest annual figure on record is 45.7% in fiscal 2018.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -113.8% | +158.8 |
| FY2024 | Dec 31, 2024 | -272.5% | +19.4 |
| FY2023 | Dec 31, 2023 | -292.0% | −43.3 |
| FY2022 | Dec 31, 2022 | -248.7% | −275.9 |
| FY2021 | Dec 31, 2021 | 27.2% | +99.2 |
| FY2020 | Dec 31, 2020 | -72.0% | +196.9 |
| FY2019 | Dec 31, 2019 | -268.9% | −314.6 |
| FY2018 | Dec 31, 2018 | 45.7% | +749.8 |
| FY2017 | Dec 31, 2017 | -704.0% | +668.1 |
| FY2016 | Dec 31, 2016 | -1372.1% | −1071.5 |
| FY2015 | Dec 31, 2015 | -300.6% | −235.2 |
| FY2014 | Dec 31, 2014 | -65.4% | +23.1 |
| FY2013 | Dec 31, 2013 | -88.5% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 21.0% | +352.8 |
| Q1 FY2026 | Mar 31, 2026 | -1408.6% | −1415.4 |
| Q4 FY2025 | Dec 31, 2025 | -221.3% | +19.9 |
| Q3 FY2025 | Sep 30, 2025 | -208.3% | +38.0 |
| Q2 FY2025 | Jun 30, 2025 | -331.8% | −94.1 |
| Q1 FY2025 | Mar 31, 2025 | 6.8% | +412.2 |
| Q4 FY2024 | Dec 31, 2024 | -241.3% | +41.8 |
| Q3 FY2024 | Sep 30, 2024 | -246.3% | −32.3 |
| Q2 FY2024 | Jun 30, 2024 | -237.7% | +123.0 |
| Q1 FY2024 | Mar 31, 2024 | -405.4% | −57.0 |
| Q4 FY2023 | Dec 31, 2023 | -283.1% | −91.9 |
| Q3 FY2023 | Sep 30, 2023 | -214.0% | +70.7 |
| Q2 FY2023 | Jun 30, 2023 | -360.7% | −151.9 |
| Q1 FY2023 | Mar 31, 2023 | -348.4% | −3.1 |
| Q4 FY2022 | Dec 31, 2022 | -191.2% | −265.0 |
| Q3 FY2022 | Sep 30, 2022 | -284.7% | −94.9 |
| Q2 FY2022 | Jun 30, 2022 | -208.8% | +52.8 |
| Q1 FY2022 | Mar 31, 2022 | -345.3% | −79.8 |
| Q4 FY2021 | Dec 31, 2021 | 73.8% | +289.4 |
| Q3 FY2021 | Sep 30, 2021 | -189.8% | −198.7 |
| Q2 FY2021 | Jun 30, 2021 | -261.6% | −57.8 |
| Q1 FY2021 | Mar 31, 2021 | -265.5% | −38.6 |
| Q4 FY2020 | Dec 31, 2020 | -215.6% | +9.3 |
| Q3 FY2020 | Sep 30, 2020 | 8.9% | +244.2 |
| Q2 FY2020 | Jun 30, 2020 | -203.8% | −185.3 |
| Q1 FY2020 | Mar 31, 2020 | -226.9% | +3418.8 |
| Q4 FY2019 | Dec 31, 2019 | -224.9% | −235.4 |
| Q3 FY2019 | Sep 30, 2019 | -235.3% | +126.6 |
| Q2 FY2019 | Jun 30, 2019 | -18.5% | −45.0 |
| Q1 FY2019 | Mar 31, 2019 | -3645.7% | −3724.4 |
| Q4 FY2018 | Dec 31, 2018 | 10.6% | +794.7 |
| Q3 FY2018 | Sep 30, 2018 | -361.9% | +1188.0 |
| Q2 FY2018 | Jun 30, 2018 | 26.5% | +247.0 |
| Q1 FY2018 | Mar 31, 2018 | 78.7% | +4912.4 |
| Q4 FY2017 | Dec 31, 2017 | -784.2% | +372.0 |
| Q3 FY2017 | Sep 30, 2017 | -1549.9% | +12973.3 |
| Q2 FY2017 | Jun 30, 2017 | -220.6% | – |
| Q1 FY2017 | Mar 31, 2017 | -4833.6% | – |
| Q4 FY2016 | Dec 31, 2016 | -1156.1% | – |
| Q3 FY2016 | Sep 30, 2016 | -14523.2% | – |
See a number that looks wrong?